F. Hoffmann-La Roche AG – CRI Report

Global Capillary Blood Collection Devices Market Research Report – Forecast Till 2023

admin — Fri, 28 Dec 2018 02:47:33 +0000

Market Analysis
Blood Collection for testing assumes a fundamental role in an effective medical treatment at the hospitals, healthcare and diagnostic centers all over the world. Blood test accumulation method incorporates a chain of sequence, and each sequence of this grouping is very imperative to keep up high-quality clinical outcomes. Global capillary blood collection devices market is anticipated to grow at a CAGR of 10.0% during the forecast period 2017–2023.
It has been noticed that the medical device regulation is the key factor driving the growth of the capillary blood collection devices market. Control of the usage of a medical device must be upgraded and improvised to protect the well-being of the patient. It must be ensured that high-quality products and effective technologies reach the patients. Developing interest for analysis of chronic diseases, the rising prevalence of diabetes, and expanding geriatric populace are additionally energizing the market development. However, the higher risk related to the capillary blood assortment technologies leading to blood contaminations may restrict the growth of the capillary blood collection devices market.
Market Segmentation
The global capillary blood collection devices market is divided on the basis of its type of devices, material, and end-user industry. On the basis of its type of devices, the global capillary blood collection devices market is bifurcated into lancets, blood collecting tubes and collector, and warming devices. Based on its material, the global market is classified into glass, plastic, stainless steel, and others. Based on its end -user, the market is sectioned into clinics, hospitals, home diagnostics, diagnostic centers and pathology laboratories, and others.
Regional Analysis
Geographically, the global capillary blood collection devices market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.
Major Players
Some of major players in the capillary blood collection devices market include companies like F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Novo Nordisk A S, Medtronic PLC, B. Braun Melsungen AG, Becton Dickinson and Company, Thermo Fisher Scientific Inc., Ypsomed Holding AG, Terumo Corporation, HTL-STREFA S.A., Sarstedt AG & Co, Greiner Bio-One, Owen Mumford Ltd., Improve Medical, Weigao Group, Chengdu Rich Science Industry Co., Ltd., Nipro, Weihai Hongyu Medical Devices, Medigard, and others.

The post Global Capillary Blood Collection Devices Market Research Report – Forecast Till 2023 first appeared on CRI Report.

Global Sturge-Weber Syndrome Market Research Report – Forecast To 2023

admin — Mon, 24 Dec 2018 02:00:59 +0000

Introduction
Sturge-Weber syndrome (SWS) is a neurological disorder that is present at birth. The affected individual has a noticeable distinctive port-wine stain on the forehead, scalp, or around the eye. This stain is a birthmark caused by a blood vessel abnormality. A large number of people with SWS also suffers from seizures or convulsions. Sturge-Weber syndrome develops a blood vessel abnormality called leptomeningeal angiomas in the brain. Other features of this SWS syndrome include glaucoma, paralysis, developmental delay, and intellectual disability. The person suffering from this may also have other complications such as increased pressure in the eye, developmental delays, and weakness on one side of the body. However, the factors responsible for market growth include technological advancements, increasing awareness among people, and increasing government assistance.
However, increasing challenges in research and development, the high cost of treatment, and poor healthcare system may hamper the market growth.
The global sturge-weber syndrome market has been segmented by type, diagnosis and treatment, and end user.
The global sturge-weber syndrome market has been divided, by type into type 1, type 2 and type 3.
Based on diagnosis and treatment, the global sturge-weber syndrome market has been categorized into diagnosis and treatment.
On the basis of end user, the market has been classified as hospitals and clinics and diagnostic centers.
The global sturge-weber syndrome market was valued at USD 2277.4 million in 2017 and is expected to register a CAGR of 5.3 % during the forecast period from 2018 to 2023.

Key Players
Some of the key players in the global sturge-weber syndrome market are Abbott, Pfizer Inc, F. Hoffmann-La Roche AG, Novartis AG, UCB SA, Sanofi, Shire, Aleva Neurotherapeutics SA, GW Pharmaceuticals, PLC, ElectroCore LLC, and Johnson & Johnson.
Objectives of the Study
? To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global sturge-weber syndrome market
? To provide insights into factors influencing and affecting market growth
? To provide historical and forecast revenue of market segments and sub-segments with respect to countries
? To provide strategic profiling of key players in the market and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
? To provide economic factors that influence the global sturge-weber syndrome market
? To provide a detailed analysis of the value chain and supply chain of the global sturge-weber syndrome market
Target Audience
? Potential Investors
? Associations
? Government Research Institutes
? End Users
? Raw Material Suppliers
? Drugs Suppliers and Manufacturers
Key Findings
? The global sturge-weber syndrome market is expected to reach USD 2277.4 million by 2023 at a CAGR of 5.3 % from 2018 to 2023.
? On the basis of type, the type 1 segment accounted for the largest market share of 47.44% in 2017 and is expected to be USD 792.6 million by 2023.
? The market in the Americas is expected to account for the largest share of the global sturge-weber syndrome market and is projected to reach USD 812.2 million by 2023.
? The market in Asia-Pacific is projected to be the fastest growing at a CAGR of 5.9 % from 2018 to 2023.

Regional Analysis
? Americas
o North America
? US
? Canada
o Latin America
? Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
? Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific
? Middle East & Africa
o Middle East
o Africa

The post Global Sturge-Weber Syndrome Market Research Report – Forecast To 2023 first appeared on CRI Report.

Global Active Pharmaceutical Ingredients Market Research Report – Forecast to 2023

admin — Fri, 07 Dec 2018 02:40:51 +0000

Introduction
Active pharmaceutical ingredient (API) is a biologically active pharmaceutical drug. API can be obtained by a synthetic process or from natural sources. The increasing occurrence of chronic diseases, rising acceptance, and uptake of pharmaceuticals, growth in abbreviated new drug applications (ANDA), and the growing importance of generics are expected to drive market growth. For instance, according to the report published by the Centers for Disease Control and Prevention (CDC), nearly 92.1 million adults in the US dealt with at least one type of cardiovascular diseases in 2017. However, stringent regulatory policies and adverse drug price control policies across numerous countries may hamper the growth of the market.
The global active pharmaceutical ingredient market is expected to reach to a market value of USD 215,125.4 million by 2023 from USD 161,143.2 million in 2017 and is expected to register a CAGR of 4.93% during the forecast period from 2018 to 2023. In 2016, the market was led by the Americas with a 40.7% share, followed by Europe and Asia-Pacific with shares of 27.0% and 24.8%, respectively. The increasing burden of chronic diseases has been observed in different parts of the world which has upsurge the growth of the market.
The global active pharmaceutical ingredients market is segmented by manufacturing process, by type of synthesis, by API formulation, by application, by molecule, and by region.
The global active pharmaceutical ingredients market, by manufacturing process, is segmented into captive manufacturing and contract manufacturing.
The global active pharmaceutical ingredients market, by type of synthesis, is segmented into synthetic and biotech.
The global active pharmaceutical ingredients market, by API formulation, is segmented into generic API and innovative API.
By application, the global active pharmaceutical ingredients market is segmented into cardiovascular disease, oncology, neurological disorders, orthopedic disorders, respiratory, gastrointestinal disorders, urology, and others.
By molecule, the global active pharmaceutical ingredients market is segmented into small molecule and large molecule.
The global active pharmaceutical ingredient market is expected to reach to a market value of USD 215,125.4 million by 2023 from USD 161,143.2 million in 2017 and is expected to register a CAGR of 4.93% during the forecast period from 2018 to 2023.
Key Players
Sanofi, Bayer AG, Pfizer Inc., F. Hoffmann-La Roche AG, Abbott Laboratories, Merck & Co., Inc, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc (GSK), Novartis AG, Eli Lilly and Company, and Teva Pharmaceutical Industries Ltd, and others.
Study objectives
• To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the active pharmaceutical ingredients market
• To provide insights into factors affecting the market growth
• To analyze the global active pharmaceutical ingredients market based on various tools such as supply chain analysis and Porter’s five force analysis
• To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries
• To provide country-level analysis of the market with respect to current market size and future perspective
• To provide country-level analysis of the market for segments by manufacturing process, by type of synthesis, by API formulation, by application, by molecule, and by region
• To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the active pharmaceutical ingredients market
Target Audience
• Pharmaceutical and Biotechnology Companies
• Research and Development (R&D) Companies
• Government Research Institutes
• Academic Institutes and Universities
Key Findings
• The global active pharmaceutical ingredients market is expected to reach USD 215,125.4 million by 2023 from USD 161,143.2 million in 2017 and is expected to register a CAGR of 4.93% during the forecast period from 2018 to 2023.
• On the basis of manufacturing process, the captive manufacturing segment is expected to account for the largest market share at a CAGR of 4.78% by 2023
• Based on type of synthesis, the synthetic segment is expected to account for the largest market share at a CAGR of 4.89% by 2023
• Based on API formulation, the generic API segment is expected to account for the largest market share at a CAGR of 4.62% by 2023
• Based on application, the cardiovascular disease segment is expected to account for the largest market share at a CAGR of 3.74% by 2023
• Based on molecule, the small molecule segment is expected to account for the largest market share at a CAGR of 4.89% by 2023
• The Americas is expected to hold the largest share of the global active pharmaceutical ingredients market at a CAGR of 4.74% by 2023
• Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 5.27% by 2023
Regional Analysis
• Americas
o North America
 US
 Canada
o South America
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o Republic of Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa

The post Global Active Pharmaceutical Ingredients Market Research Report – Forecast to 2023 first appeared on CRI Report.

Global Creatinine Test Market Research Report – Forecast to 2023

admin — Tue, 04 Dec 2018 07:30:43 +0000

Introduction
Creatinine test is a type of blood test that measures the level of creatinine in the blood. When creatine, an amino acid found in the muscle, breaks down, it forms a waste product known as creatinine. It is a waste product that the kidneys normally eliminate from the body. Creatinine levels in the blood help to determine if the kidneys are working well. The growing prevalence of chronic kidney diseases, technological advancements in the kidney function testing, and initiatives taken by the government to control chronic kidney diseases are expected to drive market growth. According to a study published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in December 2016, the overall prevalence of chronic kidney diseases (CKD) in the US was approximately 14%. However, false estimates of creatinine tests may hamper the growth of the market.
The global creatinine test market is expected to reach a market value of USD 604.55 million by 2023 from USD 407.41 million in 2016 and is expected to register a CAGR of 5.8% during the forecast period from 2017 to 2023. In 2016, the Americas held the highest share of the market at 35.4%, followed by Europe and Asia-Pacific with shares of 31.4% and 20.5%, respectively. The increasing prevalence of kidney diseases worldwide is expected to increase the growth of the market during the forecast period.
The global creatinine test market is segmented into test type, product type, application, end user, and region.
The global creatinine test market, by test type, is segmented into blood test, urine test, and creatinine clearance test.
The global creatinine test market, by product type, is segmented into consumables and instruments.
The global creatinine test market, by application, is segmented into urinary tract obstruction, renal failure, kidney cancer, and glomerulonephritis.
By end user, the global creatinine test market is segmented into hospitals and clinics, diagnostic centers, and research institutes.
The global creatinine test market is expected to have a value of USD 604.55 million by 2023 from USD 407.41 million in 2017 and is expected to register a CAGR of 5.8% during the forecast period from 2017 to 2023.
Key Players
Siemens AG, Abbott, Thermo Fisher Scientific Inc, Abcam plc, F. Hoffmann-La Roche AG, Nova Biomedical, ACON Laboratories, Inc., OPTI Medical Systems, URIT Medical, Quest Diagnostics, ARKRAY, Inc., and Danaher
Study objectives
• To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the creatinine test market
• To provide insights into factors affecting the market growth
• To analyze the global creatinine test market based on various tools such as supply chain analysis and Porter’s five force analysis
• To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries
• To provide the country-level analysis of the market with respect to the current market size and future perspective
• To provide country-level analysis of the market for segments by test type, product type, application, end user, and region
• To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the creatinine test market
Target Audience
• Diagnostic Centers
• Research and Development (R&D) Companies
• Government Research Institutes
• Academic Institutes and Universities
Key Findings
• The global creatinine test market is expected to reach USD 604.55 million by 2023 at a CAGR of 5.8 % from 2017 to 2023
• On the basis of test type, blood tests are expected to account for the largest market share at a CAGR of 5.32% by 2023
• On the basis of product type, consumables are expected to account for the largest market share at a CAGR of 5.59% by 2023
• On the basis of application, urinary tract obstruction is expected to account for the largest market share at a CAGR of 5.10% by 2023
• On the basis of end user, hospitals and clinics are expected to account for the largest market share at a CAGR of 5.30% by 2023
• The Americas is expected to hold the largest share of the global creatinine test market at a CAGR of 5.91% by 2023
• Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 6.33% by 2023
Regional Analysis
• Americas
o North America
 US
 Canada
o South America
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o Republic of Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa

The post Global Creatinine Test Market Research Report – Forecast to 2023 first appeared on CRI Report.